3 results
Approved WMOCompleted
RO5479599 is an investigational drug which is investigated by F.Hoffmann-La Roche and the Center for Personalized Cancer Treatment for the treatment of locally advanced or metastatic solid tumors with HER3 overexpression.Substudy BP27771/IMGThe…
Approved WMOCompleted
The primary objective of this study is to compare the Overall Survival (OS) of first-linemaintenance therapy with erlotinib versus erlotinib administered at the time of diseaseprogression in patients with histologically documented, advanced or…
Approved WMORecruiting
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.